U.S. FDA advisory panel backs Takeda bowel disease drug<p><a href="http://news.yahoo.com/u-fda-advisory-panel-backs-takeda-bowel-disease-000246838--finance.html"><img src="http://l.yimg.com/bt/api/res/1.2/1AWDIMbL_mFB9DFQzS5FpQ--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-12-09T225014Z_1_CBRE9B81RFX00_RTROPTP_2_SWITZERLAND.JPG" width="130" height="86" alt="The logo of Japanese Takeda Pharmaceutical Co is seen at an office building in Glattbrugg" align="left" title="The logo of Japanese Takeda Pharmaceutical Co is seen at an office building in Glattbrugg" border="0" /></a>An advisory panel of medical experts on Monday voted to recommend that U.S. health regulators approve an experimental drug for ulcerative colitis and Crohn's disease developed by Takeda Pharmaceutical Co. The panel voted by wide margins that the benefits outweigh the risks of the biotech drug, vedolizumab, and advised the Food and Drug Administration to approve it for both ulcerative colitis and Crohn's disease in patients who have not been helped by prior therapies. The FDA typically follows the recommendations of its expert advisory panels, but is not obligated to do so.</p><br clear="all"/>
Source: U.S. FDA advisory panel backs Takeda bowel disease drug (http://news.yahoo.com/u-fda-advisory-panel-backs-takeda-bowel-disease-000246838--finance.html)